Suggested remit: To appraise the clinical and cost effectiveness of veliparib within its marketing authorisation for treating BRCA-positive, human epidermal growth factor 2 (HER2)-negative, breast advanced cancer.
Status In progress
Process STA 2018
ID number 1404

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
23 October 2019 - 20 November 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
13 February 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance